NASDAQ:LEGN Legend Biotech (LEGN) Stock Price, News & Analysis $17.83 +0.03 (+0.17%) As of 03:04 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Legend Biotech Stock (NASDAQ:LEGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Legend Biotech alerts:Sign Up Key Stats Today's Range$17.56▼$18.2850-Day Range$17.00▼$22.6052-Week Range$16.24▼$37.50Volume1.42 million shsAverage Volume2.42 million shsMarket Capitalization$3.45 billionP/E RatioN/ADividend YieldN/APrice Target$55.07Consensus RatingModerate Buy Company Overview Legend Biotech Corporation (NASDAQ: LEGN) is a biotechnology company focused on developing, manufacturing and commercializing cell therapies for cancer and other serious diseases. Its research centers on chimeric antigen receptor T-cell (CAR-T) therapies, which use genetically modified immune cells to recognize and attack cancer cells. The company’s leading product is Carvykti (ciltacabtagene autoleucel), a B-cell maturation antigen (BCMA)-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend Biotech developed Carvykti in collaboration with Janssen Biotech, part of Johnson & Johnson, which is responsible for commercialization in collaboration with Legend in applicable markets. Founded in 2014, Legend Biotech is headquartered in Somerset, New Jersey, and maintains operations and research capabilities in the United States and China. In addition to Carvykti, the company is advancing a pipeline of investigational cell therapies designed to address hematologic malignancies and potentially other diseases.AI Generated. May Contain Errors. Read More Legend Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreLEGN MarketRank™: 2.76236191478 of 5 starsLegend Biotech scored higher than 55% of companies evaluated by MarketBeat, and ranked 455th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingLegend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on no strong buy ratings, 9 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialLegend Biotech has a consensus price target of $55.50, representing about 213.5% upside from its current price of $17.71.Amount of Analyst CoverageLegend Biotech has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Legend Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Legend Biotech are expected to grow in the coming year, from ($0.09) to $1.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Legend Biotech is -70.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Legend Biotech is -70.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Legend Biotech's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.46% of the float of Legend Biotech has been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 7.09.Change versus previous monthShort interest in Legend Biotech has recently increased by 11.96%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment-0.02 News SentimentLegend Biotech has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Legend Biotech this week, compared to 4 articles on an average week.Search Interest4 people have searched for LEGN on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows9 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $308,550.00 in company stock.Percentage Held by Insiders0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Legend Biotech's insider trading history. Receive LEGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LEGN Stock News HeadlinesHead to Head Contrast: Legend Biotech (NASDAQ:LEGN) and Connect Biopharma (NASDAQ:CNTB)October 11 at 7:45 AM | americanbankingnews.comLegend Biotech (NASDAQ:LEGN) Stock Price Target Cut by JPMorgan Chase & Co.October 11 at 1:54 AM | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 13 at 1:00 AM | InvestorPlace (Ad)Legend Biotech (NASDAQ:LEGN) and Q32 Bio (NASDAQ:QTTB) Head-To-Head SurveyOctober 6, 2026 | americanbankingnews.comLegend Biotech (LEGN) Tests Its Valuation After Fresh CARVYKTI Five Year DataOctober 4, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Legend Biotech (LEGN)October 3, 2026 | theglobeandmail.comInsider Selling: Legend Biotech (NASDAQ:LEGN) Director Sells $258,920.20 in StockOctober 2, 2026 | insidertrades.comInsider Selling: Legend Biotech (NASDAQ:LEGN) CFO Sells 5,430 SharesSeptember 24, 2026 | insidertrades.comSee More Headlines LEGN Stock Analysis - Frequently Asked Questions How have LEGN shares performed this year? Legend Biotech's stock was trading at $21.74 on January 1st, 2026. Since then, LEGN shares have decreased by 18.6% and is now trading at $17.7060. How were Legend Biotech's earnings last quarter? Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) released its quarterly earnings results on Tuesday, August, 11th. The company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.07 by $0.02. Legend Biotech's revenue for the quarter was up 51.9% on a year-over-year basis. Read the conference call transcript. When did Legend Biotech IPO? Legend Biotech (LEGN) raised $350 million in an IPO on Friday, June 5th 2020. The company issued 18,425,000 shares at $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO. Who are Legend Biotech's major shareholders? Top institutional shareholders of Legend Biotech include Toth Financial Advisory Corp. Insiders that own company stock include Ying Huang and Carlos E Santos. View institutional ownership trends. How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Legend Biotech investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Rocket Lab (RKLB), CRISPR Therapeutics (CRSP), Micron Technology (MU), ImmunityBio (IBRX) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/11/2026Today10/13/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 LEGN's financial health is in the Red zone, according to TradeSmith. LEGN has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LEGN CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees2,965Year Founded2014Price Target and Rating Average Price Target for Legend Biotech$55.07 High Price Target$74.00 Low Price Target$24.00 Potential Upside/Downside+208.9%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$296.80 million Net Margins-7.21% Pretax Margin-4.42% Return on Equity-8.71% Return on Assets-5.40% Debt Debt-to-Equity RatioN/A Current Ratio3.04 Quick Ratio2.94 Sales & Book Value Annual Sales$1.03 billion Price / Sales3.36 Cash FlowN/A Price / Cash FlowN/A Book Value$5.43 per share Price / Book3.28Miscellaneous Outstanding Shares193,770,000Free Float193,730,000Market Cap$3.45 billion OptionableOptionable Beta0.57 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:LEGN) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Corporation Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LEGN Stock Alerts